S48 New Aspects of Adipose Regulation

Program: Symposia
Basic/Translational Session
Sunday, April 3, 2016: 8:15 AM-9:45 AM
Room 258 (BCEC)
Chair:
Aaron Martin Cypess, MD, PhD, MMSc, National Institute of Diabetes and Digestive and Kidney Diseases/NIH, Bethesda, MD

Disclosures:
AMC: , Chugai Pharma, Principal Investigator, Molecular Metabolism. Disclosure Not Provided: EDR
8:15 AM
Philipp E Scherer, PhD, Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
Disclosures:
PES: Investigator, Takeda, Investigator, Merck & Co..
8:45 AM
Sven M Enerb├Ąck, MD, PhD, Department of Medical Genetics, University of Gothenburg, Gothenburg, Sweden
Nothing to Disclose: SME
9:15 AM
Alan R Saltiel, PhD, Medicine, University of California, San Diego, La Jolla, CA
Nothing to Disclose: ARS
See more of: Symposia

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire